Peprah Boaitey Kwame, Tuck Chloe
Pharmaceutical Society of Ghana, Accra, Ghana.
School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.
Med Access Point Care. 2020 Oct 12;4:2399202620962299. doi: 10.1177/2399202620962299. eCollection 2020 Jan-Dec.
Providing access to quality-assured medicines is a fundamental component of strengthening health systems. Yet, the World Health Organization (WHO) estimates that 13.6% of all medicines in low- and middle-income countries (LMIC's) may be substandard or falsified (SF) impeding patient outcomes, imposing financial burden, and contributing to antimicrobial resistance. Circulation of SF medicines also undermines trust in the health system and legitimate health care professionals. It may erode trust in the manufacturers of genuine pharmaceutical products as well as health professionals who prescribe and dispense them. Failure to address challenges in medicines quality assurance and supply risks jeopardizing progress towards universal healthcare coverage. This editorial draws on perspectives from a Ghanaian context and highlights the importance of ensuring an adequate and stable medicine supply, specifically through mechanisms to foster local manufacturing. This will serve to address the problem of SF medicines, as well as providing opportunities for mutual benefit with multiple related sectors. The WHO's mechanism on substandard and falsified medical products 2020 highlights multiple sectors have a key role in combatting SF medicines. Although key considerations and initiatives in other sectors are beyond the scope of this article, local manufacturing should be viewed with WHO's a multilevel systemwide approach.
提供有质量保证的药品是加强卫生系统的一个基本组成部分。然而,世界卫生组织(WHO)估计,低收入和中等收入国家(LMIC)中13.6%的药品可能是不合格或伪造的(SF),这会妨碍患者治疗效果,带来经济负担,并助长抗菌药物耐药性。SF药品的流通还会破坏对卫生系统和合法医疗保健专业人员的信任。它可能会削弱对正品药品制造商以及开处方和配药的卫生专业人员的信任。未能应对药品质量保证和供应方面的挑战可能会危及全民医疗覆盖的进展。这篇社论借鉴了加纳的情况,强调了确保充足和稳定药品供应的重要性,特别是通过促进本地生产的机制。这将有助于解决SF药品问题,并为与多个相关部门实现互利提供机会。WHO 2020年关于不合格和伪造医疗产品的机制强调,多个部门在打击SF药品方面发挥着关键作用。虽然其他部门的关键考虑因素和举措不在本文讨论范围内,但应从WHO的全系统多层次方法的角度看待本地生产。